Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Carfilzomib in Recurrent Multiple Myeloma: NCT07082270 Clinical Landscape Report 2026
15 October 2026
NCT07082270 clinical landscape for Recurrent Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab/Hyaluronidase-fihj in Multiple Myeloma: NCT07085728 Clinical Landscape Report 2026
15 October 2026
NCT07085728 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludeoxyglucose F-18 in Multiple Sclerosis: NCT07087106 Clinical Landscape Report 2026
15 October 2026
NCT07087106 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Adze1.C(Adze Biotechnology) in Metastatic melanoma: NCT07086105 Clinical Landscape Report 2026
15 October 2026
NCT07086105 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA CAR-T cells(Leman Biotech) in Plasma Cell Leukemia: NCT07085559 Clinical Landscape Report 2026
15 October 2026
NCT07085559 clinical landscape for Plasma Cell Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Fludarabine Phosphate in Idiopathic Inflammatory Myopathies: NCT07085104 Clinical Landscape Report 2026
15 October 2026
NCT07085104 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
VT-7208 in Multiple Sclerosis: NCT07085507 Clinical Landscape Report 2026
15 October 2026
NCT07085507 clinical landscape for Multiple Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enfortumab Vedotin-ejfv in Renal Pelvis and Ureter Urothelial Carcinoma: NCT07087860 Clinical Landscape Report 2026
15 October 2026
NCT07087860 clinical landscape for Renal Pelvis and Ureter Urothelial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and developmen…
9 min read
PF-08046876 in Pancreatic adenocarcinoma: NCT07090499 Clinical Landscape Report 2026
15 October 2026
NCT07090499 clinical landscape for Pancreatic adenocarcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tetravalent dengue virus vaccine(Instituto Butantan) in Dengue: NCT07087912 Clinical Landscape Report 2026
15 October 2026
NCT07087912 clinical landscape for Dengue: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Omacetaxine Mepesuccinate in Refractory acute myeloid leukemia: NCT07091006 Clinical Landscape Report 2026
15 October 2026
NCT07091006 clinical landscape for Refractory acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Velinotamig in Multiple Myeloma: NCT07090954 Clinical Landscape Report 2026
15 October 2026
NCT07090954 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.